NCT03539445View on ClinicalTrials.gov

Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

1,216

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

May 22, 2022

Study Completion Date

July 31, 2022

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Butylphthalide

This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.

DRUG

Butylphthalide Placebo

This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.

Trial Locations (1)

100050

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT03539445 - Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment | Biotech Hunter | Biotech Hunter